openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Spero Therapeutics, Inc. (NASDAQ: SPRO)

09-23-2022 02:34 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Spero Therapeutics, Inc. (NASDAQ: SPRO) shares.

An investigation on behalf of current long term investors in Spero Therapeutics, Inc. (NASDAQ: SPRO) shares.

An investigation was announced for current long-term investors in shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) concerning potential breaches of fiduciary duties by certain directors of Spero Therapeutics, Inc..

Investors who are current long term investors in Spero Therapeutics, Inc. (NASDAQ: SPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: SPRO stocks follows a lawsuit filed against Spero Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SPRO stocks, concerns whether certain Spero Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that the data submitted in support of the Tebipenem HBr NDA were insufficient to obtain FDA approval, that accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form, that the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) here

News-ID: 2746596 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Revance Therapeutics, Inc …
An investor, who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC), filed a lawsuit over alleged violations of Federal Securities Laws by Revance Therapeutics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 29, 2024 and December 6, 2024, and / or those who purchased anyNASDAQ: RVNC shares prior to February 2024 and continue
Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDAQ: AZN)
Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDA …
An investor, who purchased shares of AstraZeneca PLC (NASDAQ: AZN), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by AstraZeneca PLC in connection with certain allegedly false and misleading statements made between February 23, 2022 and December 17, 2024. Investors who purchased a significant amount of shares of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, have certain options and for certain
Lawsuit filed for Investors who lost money with shares of Applied Therapeutics, Inc. (NASDAQ: APLT)
Lawsuit filed for Investors who lost money with shares of Applied Therapeutics, …
An investor, who purchased shares of Applied Therapeutics, Inc. (NASDAQ: APLT), filed a lawsuit over alleged violations of Federal Securities Laws by Applied Therapeutics, Inc. Investors who purchased shares of Applied Therapeutics, Inc. (NASDAQ: APLT) have certain options and for certain investors are short and strict deadlines running. Deadline: February 18, 2025. NASDAQ: APLT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. New York based Applied
Investigation announced for Long-Term Investors in shares of WEBTOON Entertainment Inc. (NASDAQ: WBTN) over possible Wrongdoing
Investigation announced for Long-Term Investors in shares of WEBTOON Entertainme …
An investigation on behalf of current long-term investors in shares of WEBTOON Entertainment Inc. (NASDAQ: WBTN) concerning potential breaches of fiduciary duties by certain directors of WEBTOON Entertainment Inc. was announced. Investors who are current long term investors in WEBTOON Entertainment Inc. (NASDAQ: WBTN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long

All 5 Releases


More Releases for Spero

Artificial (Plant Based) Egg Market Growth Analysis And Trends In The Global Ind …
LOS ANGELES, United States: QY Research has recently published a new report, titled Global Artificial (Plant Based) Egg Market Outlook 2022 This report offers an in-depth analysis of the global Artificial (Plant Based) Egg market taking into account market dynamics, segmentation, geographical expansion, and competitive landscape, and various other key aspects. The market analysts who have prepared the report have thoroughly studied the global Artificial (Plant Based) Egg market and have offered
Lawsuit filed for Investors in shares of Spero Therapeutics, Inc. (NASDAQ: SPRO)
An investor, who purchased shares of Spero Therapeutics, Inc. (NASDAQ: SPRO), filed a lawsuit against Spero Therapeutics, Inc over alleged violations of Federal Securities Laws. Investors who purchased shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) have certain options and for certain investors are short and strict deadlines running. Deadline: July 25, 2022. NASDAQ: SPRO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Cambridge, MA based Spero
South and Central America Carbapenem-Based Antibiotics Market Unexpected Growth …
The latest South and Central America Carbapenem-Based Antibiotics Market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thorough analysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. This study can be described as most wide-ranging documentation that comprises all the aspects of
01-21-2021 | Health & Medicine
Fact.MR
Carbapenem-based Antibiotics Market to Exhibit 7% CAGR, with Sales of Tebipenem …
Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 - 2021. Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of
Socket Set Market Outlook to 2023 – Stanley (Dewalt), Snap-On, Great Star, Cra …
In the Global Socket Set Industry Market Analysis & Forecast 2018-2023, the revenue is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2023, growing at a CAGR of XX% between 2018 and 2023. The production is estimated at XX million in 2017 and is forecasted to reach XX million by the end of 2023, growing at a CAGR of
Global Wrench Market Forecast 2018-2025 WRENCH SMARTPROJECT, Allen, SPERO, Reed
A market study "Global Wrench Market" examines the performance of the Wrench market 2018. It encloses an in-depth Research of the Wrench market state and the competitive landscape globally. This report analyzes the potential of Wrench market in the present and the future prospects from various angles in detail. The Global Wrench Market 2018 report includes Wrench market Revenue, market Share, Wrench industry volume, market Trends, Wrench Growth aspects. A wide